Detection of adventitious viruses in biologicals - A rare occurrence

Developments in Biologicals

Volumn 123, Issue , 2006, Pages 153-164

  Nims, R W ^a,b  

^a Invitrogen Bioservices   (United States)

^b BioReliance   (United States)

Author keywords

Adventitious viral contaminants; Biologicals testing; In vitro virus screen

Indexed keywords

VACCINE;

ANIMAL; CELL LINE; CONFERENCE PAPER; DISEASE TRANSMISSION; DRUG CONTAMINATION; DRUG LEGISLATION; GENE THERAPY; HUMAN; ISOLATION AND PURIFICATION; SAFETY; STANDARD; UNITED STATES; VIRUS; VIRUS INFECTION;

ANIMALS; CELL LINE; DRUG CONTAMINATION; GENE THERAPY; HUMANS; LEGISLATION, DRUG; SAFETY; UNITED STATES; VACCINES; VIRUS DISEASES; VIRUSES;

EID: 33644625267     PISSN: 14246074     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Conference Paper

References (23)

1. Dusing SK: Cell line characterization, in Sofer G, Zabriskie DW (eds): Biopharmaceutical Process Validation. New York, Marcel Dekker, 2000, pp 77-99.
2. Whiteman MD: Scope and practicality of in vivo testing for adventitious agents, in Petricciani J, Sheets R (eds): Vaccine Cell Substrates 2004. Dev Biol (Basel). Basel, Karger, 2006, vol 123, pp 147-152.
3. nd edition, New York, Raven Press, Ltd, 1991, pp 267-289.
4. Code of Federal Regulations: Animals and Animal Products. Title 9, Part 113.53 (US Government Printing Office, Washington, DC), 2003.
5. International Conference on Harmonization: Guideline on Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin (ICH 5A, 1997). Geneva, Switzerland, International Conference on Harmonization, 1997.
6. International Conference on Harmonization: Guideline on Quality of Biotechnological/Biological Products: Derivation and Characterization of Cell Substrates Used in the Production of Biotechnological/Biological Products (ICH Q5D, 1997). Geneva, Switzerland, International Conference on Harmonization, 1997.
7. FDA/CBER: Points to Consider in the Characterization of Cell Lines Used to Produce Biologicals (FDA/CBER, 1993) Rockville, MD: Food and Drug Administration, Center for Biologics Evaluation and Research, 1993.
8. FDA/CBER: Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use (FDA/CBER, 1997) Rockville, MD: Food and Drug Administration, Center for Biologics Evaluation and Research, 1997.
9. FDA/CBER: Guidance for Industry: Guidance for Human Somatic Cell Therapy and Gene Therapy (FDA/CBER, 1998) Rockville, MD: Food and Drug Administration, Center for Biologics Evaluation and Research, 1998.
10. Coffin J: Significance of retrovirus contaminants of cell substrates (Abstract), in Petricciani J, Sheets R (eds): Vaccine Cell Substrates 2004. Dev Biol (Basel). Basel, Karger, 2006, vol 123, p 89.
11. Jarret R, Johnson D, Wilson K, Gallagher A: Molecular Methods for Virus Discovery, in Petricciani J, Sheets R (eds): Vaccine Cell Substrates 2004. Dev Biol (Basel). Basel, Karger, 2006, vol 123, pp 77-88.
12. Chang A, Dusing S: Practical assay issues with PERT/PBRT assay: A highly sensitive reverse transcriptase assay, in Petricciani J, Sheets R (eds): Vaccine Cell Substrates 2004. Dev Biol (Basel). Basel, Karger, 2006, vol 123, pp 91-87.
13. EMEA/CPMP (European Agency for the Evaluation of Medicinal Products. Committee for Proprietary Medicinal Products): Note for Guidance on the use of Bovine serum in the manufacture of human biological medicinal products. London, 2003, pp 1-8.
14. Schuurman R, van Steenis B, van Strien A, van der Noordaa J, Sol C: Frequent detection of bovine polyomavirus in commercial batches of calf serum by using the polymerase chain reaction. J Gen Virol 1991; 72: 2739-2745.
15. Kappeler A, Lutz-Wallace C, Sapp T, Sidhu M: Detection of bovine polyomavirus contamination in fetal bovine sera and modified live viral vaccines using polymerase chain reaction. Biologicals 1996; 24 (2): 131-135.
16. Potts BJ, Kivens WJ: Detecting and removing porcine viruses to prevent contamination of biopharmaceutical raw materials. BioPharm 2000; 26-31.
17. Garnick RL: Experience with viral contamination in cell culture, in Brown F, Lubiniecki AS (eds): Viral Safety and Evaluation of Viral Clearance from Biopharmaceutical Products. Dev Biol Stand. Basel, Karger, 1996 vol 88, pp 49-56.
18. Jacoby RO, Ball-Goodrich LJ, Besselsen DG, McKisic MD, Riley LK, Smith AL: Rodent parvovirus infections. Lab Anim Sci 1996; 46: 370-380.
19. Nettleton PF, Rweyemamu MM: The association of calf serum with the contamination of BHK21 clone 13 suspension cells by a parvovirus serologically related to the Minute Virus of Mice (MVM). Arch Virol 1980; 64: 359-374.
20. Zoletto R: Parvovirus serologically related to the minute virus of mice (MVM) as contaminant of BHK 21 cl. 13 suspension cells, in Spier R, Griffiths B, Hennessen W (eds): Production and Exploitation of Existing and New Animal Cell Substrates. Dev Biol Stand. Basel, Karger, 1985, vol 60, pp 179-183.
21. Tattersall P, Bratton J: Reciprocal productive and restrictive virus-cell interactions of immunosuppressive and prototype strains of minute virus of mice. J Virol 1983; 46 (3): 944-955.
22. Rabenau H, Ohlinger V, Anderson J, Selb B, Cinatl J, Wolf W, Frost J, Mellor P, Doerr HW: Contamination of genetically engineered CHO-cells by epizootic haemorrhagic disease virus (EHDV). Biologicals 1993; 21: 207-214.
23. Oehmig A, Buttner M, Weiland F, Werz W, Bergemann K, Pfaff P: Identification of a calicivirus isolate of unknown origin. J Gen Virol 2003; 84: 2837-2845.